Microviable Therapeutics SL received funding under Eurostars-3 Program co-financed by CDTI (Spanish National Agency) and the Research and Innovation Funding Program Horizon Europe.
The project “Microbiome-based medicinal products to increase the efficacy of immunotherapy” MICROBOOST, is focused on the development of novel biological medicines based on human intestinal bacteria to increase the efficacy of immunotherapy in melanoma and lung cancer. This objective involves the use of specific bacterial strains to create defined bacterial consortia (LBPs) and the evaluation of efficacy and mechanisms of action in preclinical models of oncology as an adjuvant to immunotherapy.
Thanks to the international collaboration with Experimentica, this novel medicines will be developed using preclinical models of 3D cultures. The project MICROBOOST is co-financed by Centro para Desarrollo Tecnológico y la Innovación (CDTI).
Title: Microbiome-base medicinal products to increase the efficacy of immunotherapy.
Period:01/05/2025-01/05/2028
Budget: 395.521€
